CoreCap Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

CoreCap Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$37.5K	Buy	152 +134	+744%	+$34.1K	﹤0.01%	1529
2026 Q2	$5.42K	Buy	18 +16	+800%	+$4.83K	﹤0.01%	2268
2026 Q1	$662	Sell	2 -150	-99%	-$51K	﹤0.01%	2607
2025 Q4	$60.4K	Sell	152 -228	-60%	-$101K	﹤0.01%	1231
2025 Q3	$173K	Buy	380 +378	+18,900%	+$154K	0.01%	847
2025 Q2	$652	Hold	2	–	–	﹤0.01%	2475
2025 Q1	$540	Buy	+2	New	+$514	﹤0.01%	2667
2024 Q4	–	Sell	-2	Closed	-$550	–	2854
2024 Q3	$550	Hold	2	–	–	﹤0.01%	2352
2024 Q2	$486	Hold	2	–	–	﹤0.01%	1450
2024 Q1	$299	Buy	+2	New	+$334	﹤0.01%	2374
2022 Q4	$475	Buy	+2	New	+$427	﹤0.01%	2176

Other funds holding ALNY

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Portman Square Capital London, United Kingdom $1.77B AUM 15.29% 1-Year Est. Return

Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.8B AUM 30.39% 1-Year Est. Return

CoreCap Advisors's ALNY Position: Q3 2026 in Review

CoreCap Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 744% in Q3 2026, buying an estimated $34.1K and bringing the position to 152 shares worth $37.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1529.

CoreCap Advisors first reported a position in ALNY in Q4 2022 and has held it in 11 quarters since. The position peaked at $173K in Q3 2025. 128 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

CoreCap Advisors held 152 shares of Alnylam Pharmaceuticals worth $37.5K as of Q3 2026.
CoreCap Advisors bought 134 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $34.1K.
Alnylam Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #1529 holding.
CoreCap Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
CoreCap Advisors's Alnylam Pharmaceuticals position peaked at $173K in Q3 2025.
128 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.